News
Latest News
- 28 July 2022 – Chair’s Investor Update
- 26 July 2022 – Publication of new data on NTCD-M3
- 19 July 2022 – Positive update from US FDA on XF-73 Phase 3
- 12 July 2022 – Destiny Pharma receives award from the Cystic Fibrosis Foundation
- 07 July 2022 – Destiny Pharma announce publication of XF-73 drug synergy data
- 05 July 2022 – Destiny Pharma announces start of a new XF-73 research programme
- 27 May 2022 – Result of Annual General Meeting and Strategy Update
- 26 May 2022 – Destiny Pharma plc Board changes
- 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
- 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
- 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
- 27 April 2022 – Posting of Annual Report and Notice of AGM
- 12 April 2022 – Audited results for year ended 31 December 2021
- 31 March 2022 – Presenting data at the ECCMID 2022 Congress
- 28 March 2022 – Result of General Meeting and Total Voting Rights
- 25 March 2022 – Result of Open Offer
- 25 March 2022 – Destiny’s microbiome project article published in Vantage
- 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”
- 22 March 2022 – Exercise of Options and Total Voting Rights
- 17 March 2022 – Open Offer Application Form
- 17 March 2022 – Form of Proxy
- 09 March 2022 – Circular to shareholders
- 08 March 2022 – Fundraising
- 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme
- 01 February 2022 – Positive data in XF-73 Dermal study with NIAID
- 24 January 2022 – Clinical and commercial opportunity of NTCD-M3
- 21 January 2022 – Destiny Pharma Lancet Report
- 17 January 2022 – Strategy/Company/Ops Update